NexturnBioscience Co. Ltd (089140) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NexturnBioscience Co. Ltd (089140) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.51 Billion ≈ $3.06 Million USD) by net assets (₩240.26 Billion ≈ $162.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of NexturnBioscience Co. Ltd for the company's overall valuation and market capitalisation.
NexturnBioscience Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how NexturnBioscience Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NexturnBioscience Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NexturnBioscience Co. Ltd ranked by their cash flow conversion efficiency. Explore NexturnBioscience Co. Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pilulka Lekarny as
PR:PINK
|
N/A |
|
T3 Defense Inc.
NYSE:DFNS
|
-0.023x |
|
SDN Company. Ltd
KQ:099220
|
-0.004x |
|
Yuyu Pharma Inc
KO:000225
|
0.021x |
|
CEKD Bhd
KLSE:0238
|
0.024x |
|
Metro Bank PLC
LSE:MTRO
|
0.195x |
|
Elicera Therapeutics AB
ST:ELIC
|
-0.156x |
|
Air Industries Group
NYSE MKT:AIRI
|
0.000x |
Annual Cash Flow Conversion Efficiency for NexturnBioscience Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of NexturnBioscience Co. Ltd from 2014 to 2024. View NexturnBioscience Co. Ltd share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩136.62 Billion ≈ $92.59 Million |
₩-1.14 Billion ≈ $-774.60K |
-0.008x | +41.40% |
| 2023-12-31 | ₩138.01 Billion ≈ $93.53 Million |
₩-1.97 Billion ≈ $-1.34 Million |
-0.014x | -29.82% |
| 2022-12-31 | ₩108.27 Billion ≈ $73.38 Million |
₩-1.19 Billion ≈ $-806.98K |
-0.011x | -127.83% |
| 2021-12-31 | ₩92.73 Billion ≈ $62.85 Million |
₩3.66 Billion ≈ $2.48 Million |
0.040x | +1520.67% |
| 2020-12-31 | ₩96.77 Billion ≈ $65.58 Million |
₩235.94 Million ≈ $159.89K |
0.002x | -91.07% |
| 2019-12-31 | ₩100.16 Billion ≈ $67.88 Million |
₩2.74 Billion ≈ $1.85 Million |
0.027x | -72.91% |
| 2018-12-31 | ₩95.51 Billion ≈ $64.73 Million |
₩9.63 Billion ≈ $6.52 Million |
0.101x | +81.94% |
| 2017-12-31 | ₩91.77 Billion ≈ $62.19 Million |
₩5.08 Billion ≈ $3.45 Million |
0.055x | -72.15% |
| 2016-12-31 | ₩89.89 Billion ≈ $60.92 Million |
₩17.88 Billion ≈ $12.12 Million |
0.199x | +211.78% |
| 2015-12-31 | ₩30.04 Billion ≈ $20.36 Million |
₩1.92 Billion ≈ $1.30 Million |
0.064x | -71.37% |
| 2014-12-31 | ₩29.08 Billion ≈ $19.70 Million |
₩6.48 Billion ≈ $4.39 Million |
0.223x | -- |
About NexturnBioscience Co. Ltd
Nexturn Co.,Ltd. develops and produces CNC automatic lathe machines in Korea and internationally. It provides CNC swiss-type automatic lathe products, high temperature display glass press equipment, and automatic line-up robots, as well as an intelligent intervention robot system based on robot 3D cardiovascular visualization technology. The company was formerly known as KMT Incorporated and chan… Read more